TMD-SECURITY
TMD Security announced today the launch of a global program with consulting firm Deloitte to help banks and ATM deployers understand the annual operational cost savings and benefits from replacing physical keys and manual processes with a key-less ATM and Branch Access Management solution. Ten Deloitte customer engagements are planned in EMEA, APAC and the Americas and there is availability for a further ten free custom business case engagements before the end of the year.
“Reducing ATM operational costs has never been more critical than it is today,’’ said Cees Heuker of Hoek, CEO and Founder, TMD Security. “We are proud to announce this global relationship with Deloitte. A custom business case gives valuable insight into an ATM deployer’s specific cost savings and business benefits potential, depending on their ATM network and current access processes. Our clients discover that replacing keys and manual processes with our Access Management solution results in staggering productivity improvements and annual operational cost savings. Also, faced with the health risks associated with the COVID-19 pandemic, removing the need for keys, reducing the number of ‘meet and greets’ with key-holders at service visits, and eliminating the reliance on call centres for providing security codes brings significant safety benefits. Despite the pandemic, we can continue with the Deloitte program because interviews and data gathering can be done remotely. Interest has been strong and we are inviting ATM deployers to reserve one of the remaining slots soon.’’
TMD ATM and Branch Access Management is a key-less, centrally managed secure access solution for all types of ATMs and door locks which remotely validates the IDs of the pre-authorised user, lock and mobile device and checks the pre-approved schedule in a split second at the time of access. Randomly generated, encrypted One-Time-Codes are sent directly to the lock, with a real-time audit trail. TMD’s new Intelligent Alarm Switch integrates pre-authorised activation and deactivation of alarms in the ATM, secure room or branch into the access management solution via TMD’s One Touch Access TM Security mobile app which saves time, reduces false alerts and improves security.
“Our clients recognise that TMD Security is in a unique position to deliver proven and certified security hardware combined with intelligent software because of our sister company TMS ATM Software," added Cees. “This powerful combination of hardware and software means that we are fast to market with innovative, user-friendly access management solutions that can be tailored to our clients’ needs.’’
TMD Security will present real-world facts and figures from ATM deployers who are already reaping the benefits of key-less Access Management in a live webinar hosted by ATM Marketplace.
Company profile
TMD Security is the global leader in ATM security and ATM and Branch Access Management with headquarters in Europe and sales and support in the Americas, EMEA and APAC.
email: accessmanagement@tmdsecurity.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom